Breast Cancer Research and Treatment **23**: 259, 1992.

Author index, Volume 23

Abbate I 63
Adler SA 241
Amadori D 63
Andersen J 219

Becker M 87
Brijlall D 241
Büttner B 87

Catozzi L 63
Chamness GC 15
Correale M 63

DeLena M 63
Dhingra K 201
Díez-Itza I 251
Dilley WG 77
Dowsett M 57
Dutrillaux B 43

Eibl MM 233
Ekse D 57
Engler KS 97

Ferri G 63
Fichtner I 87
Fletcher WA 71

Gerbault-Seureau M 43
Good M-JD 223
Görlich M 87
Grady LH 97
Graves JM 51

Haagensen DE 77
Herz F 241
Hillner BE 17
Hittelman WN 201
Hortobagyi G 201
Howe JP III 13

Jacobs S 57
Johannessen DC 57
Jones A 57
Judy BM 97

Kato M 241
Kato S 241
Kim SY 201
Kopans D 223

Lamelas ML 251
Lind SE 223
Lippman ME 9
Lönn S 191
Lönn U 191
Lønning PE 57
López-Otín C 251

Magdelénat H 43
Mangia A 63
Mathiessen O 219
McNeil F 57
Mehta RR 51

Naundorf H 87
Nielsen NSM 219
Nylen U 191

O'Malley BW 8

Paradiso A 63
Piffanelli A 63
Poulsen HS 219
Powles TJ 57
Prieur M 43

Remvikos Y 43
Rewasowa EC 87
Riccobon A 63
Rivera R 211
Rosen HR 233
Russo IH 211
Russo J 211
Rutteman GR 29

Sahin A 201
Sánchez LM 251
Santen RJ 10
Smith JK 12
Smith TJ 17
Stenkvist B 191
Sterns EE 71
Stewart P 77
Stierer M 233
Supak J 201

Vennström B 191
Vizoso F 251

Wells SA 77
Welshons WV 97
Wolf HM 233

Zee B 71

Breast Cancer Research and Treatment **23**: 261-266, 1992.

Subject index, Volume 23

17β-hydroxysteroid dehydrogenase
hormone effects, paracrine interactions 51-56
4-hydroxyandrostenedione
addition of aminoglutethimide 57-62

adjuvant chemotherapy
cost-effectiveness in node-negative breast cancer 17-27
timing in conservative treatment 178
adjuvant therapy
abstracts 145-146
alkaline phosphatase
placental form induced by hyperosmolality in MCF-7 cells 241-249
aminoglutethimide
response when added to 4-hydroxyandrostenedione 57-62
amplification of DNA sequences
from multiple sites 137
androgens
and secretion of GCDFPs by T47D cells in culture 77-86
animal models
contraceptive steroids and breast cancer risk 29-41
antibody titers
impaired response to hepatitis B vaccination in breast cancer patients 233-240
antiestrogens
see endocrine therapy, tamoxifen
antigens
human milk fat globule antigens and tumor differentiation 71-76
aromatase inhibitors
aminoglutethimide adds responses to 4-hydroxyandrostenedione 57-62

bone marrow micrometastases
immunofluorescent detection, by tumor stage 136
breast conserving treatment
abstracts 161-163
local recurrence following minimal surgery 180
quantitative evaluation of residual carcinoma in re-excision 180
timing of adjuvant chemotherapy 178
breast development
morphologic analysis with age, effect of parity 211-218
breast fluid proteins
and breast cancer, reproductive history, and oral contraceptives 251-258
secretion of GCDFPs by T47D cells 77-86
breast self-examination (BSE)
assessment in women with a family history 156
bryostatin 1
in expansion of tumor-reactive T cells 183

c-erb-B2
see oncogenes
calorie restriction
in prevention 171
carcinogens
polyaromatic hydrocarbons as antiestrogens 157-158
cathepsin D
and prognosis 135
vs. proliferative activity 63-70
chemotherapy
abstracts 132-134, 142-145
dose intensity vs. survival 133
high-dose, without progenitor replacement 179
high-dose therapy/rescue, abstracts 163-166
liposomal doxorubicin, high response rate 132
model tumors for *in vivo* testing 87-95
timing during cycle affects later fertility 132
see also induction chemotherapy
chromosome abnormalities
ISH detection in normal as well as malignant mammary tissue 201-210

chromosome rearrangements
increase with proliferative activity in tumor evolution 43-49
clinical follow-up
for women with early stage breast cancer 132
clinical practice
abstracts 146-147
colony stimulating factors (CSFs)
adjunct to high-dose therapy, abstracts 164-166
and acceleration of FEC regimen 133
conservative treatment
see breast conserving treatment
contraceptive steroids
and breast cancer risk — insights from animal studies 29-41
cosmetic breast augmentation
risk and survival of subsequent breast cancer 131
cosmetic outcome
see breast-conserving treatment
cost analysis
adjuvant therapy 146
cost-effectiveness
of adjuvant chemotherapy in node-negative women 17-27
cyclin
regulation by insulin 183
gene amplification and overexpression 178
cytogenetics
increase of proliferative rate with chromosome rearrangements 43-49
non-isotopic, non-fluorescent *in situ* hybridization 201-210

decision analysis model
and cost-effectiveness of node-negative adjuvant therapy 17-27
depression
and tamoxifen 182
detection and diagnosis
abstracts 158-160
development, breast
see breast development
diagnosis
abstracts 158-160, 179-180
diagnostic interview
and psychological adjustment to cancer 172
differentiation
and reactivity with HMFG antibodies 71-76
DNA index
see ploidy
dogs
studies of contraceptive steroids and breast cancer risk 29-41
dose intensification
see high-dose therapy
drug resistance
abstracts 147-148
association with heat shock proteins 178
ductal carcinoma in situ (DCIS)
review (abstract) 157
significance of excisional margins 181

economics
cost-effectiveness of adjuvant chemotherapy 17-27
EGF receptor
and prognosis 134
double immunocytochemical assay with ER 185
in normal breast tissue vs. tumor 138
endocrine therapy
abstracts 168-170, 181-182
mammographic parenchymal pattern not a predictor of response 219-222
endocrinology of breast cancer
abstracts 154-155
endoreduplication
in breast tumor evolution model 43-49
endoscopy
in evaluation of intraductal disease 180
in diagnosis of intraductal lesions 158
epidermal growth factor (EGF)
action on MCF-7 cells in commercial charcoal-stripped serum 97-104
estrogen action
commercial charcoal-stripped serum for study 97-104
estrogen receptor
abstracts 183-185
correlation with mammographic parenchymal pattern 219-222
positive breast epithelium as a risk factor 182
estrogen sensitivity
enhancement by hormone withdrawal 184

estrogens
tumor factors stimulate estradiol formation in nonmalignant tissue 51-56
estrogens in plasma
suppression by aromatase inhibitors parallels tumor responses 57-62
ether lipids
model tumors for testing tumor cytoxicity in nude mice 87-95
evolution of breast tumors
and c-erb-B2 amplification 191-200
increase of proliferative rate with chromosome rearrangements 43-49

familial/hereditary breast cancer
linkage analysis, chromosome 17q marker 174
registry recruitment strategies 147
vascularity of hereditary breast carcinomas 147
fenretinide
in prevention, mammographic patterns 171
fibroblast growth factor (FGF)
expression in mortal and immortal breast epithelial cells 174
fine needle biopsies
for sequential analysis of oncogene amplification during tumor progression 191-200
flow cytometry
in prognosis 135

G-CSF, GM-CSF
see colony stimulating factors
garlic compounds
in prevention 171
gene amplification
frequency in breast and ovarian tumors 174
see also oncogenes
genetics
analysis in Japanese breast cancer 175
see also familial/hereditary breast cancer
genomic hybridization
rapid method for localization of genomic DNA gains and losses 137
glucocorticoids
and alkaline phosphatase, heat shock proteins 241-249
gonadatropin releasing hormone (GnRH)
in prevention regimen 171
gross cystic disease fluid proteins (GCDFPs)
androgens and secretion by T47D cells in culture 77-86
growth factors and receptors
abstracts 177, 183-185
see also EGF receptors, oncogenes
growth hormone
and mammary tumorigenesis 32-33

hamartomas of the breast
management after mammographic diagnosis 157
heat shock proteins
and drug resistance 178
induction of hsp27 by hyperosmolality in MCF-7 cells 241-249
hepatitis B vaccination
impaired response in breast cancer patients 233-240
HER-2/*neu*
see oncogenes
high-dose chemotherapy
without progenitor replacement 179
high-dose therapy/rescue
abstracts 163-166
histologic differentiation
and reactivity with HMFG antibodies 71-76
hormone therapy
see endocrine therapy

IGF-I receptors
and prognosis 151
in prediction of chemotherapy response 178
immune competence
impaired response to hepatitis B vaccination in breast cancer patients 233-240
immuno-lymphoscintigraphy
in guidance for axillary dissection 158
immunohistochemistry
reactivity with HMFG antibodies, vs. differentiation 71-76
immunotherapy
abstracts 183
in situ hybridization
for formalin-fixed mammary tissue 201-210
non-isotopic, non-fluorescent technique 201-210
induction chemotherapy
vs. mastectomy for lesions >3 cm 181

insulin
and regulation of cyclin gene 183
insulin receptor tyrosine kinase
inhibitor 184
insulin-like growth factors (IGFs)
and the anti-proliferative effects of tamoxifen 181
binding protein expression and ER status 184
receptors in human breast cancer 185
see also IGF-I receptors
interleukin-2 receptors
on peripheral blood monocytes from breast cancer patients 172

laminin binding protein
decreased expression in tumor progression 136
LDL (low-density lipoprotein)
peroxidized, cytoxicity to malignant breast cells 173
lithium
action on MCF-7 cells in commercial charcoal-stripped serum 97-104
lobular carcinoma in situ
detection and diagnosis 160
lumpectomy
see breast conserving treatment

magnetic resonance imaging (MRI)
detection of response to endocrine therapy 137
mammary tumorigenesis
and contraceptive steroids — insights from animal studies 29-41
mammographic parenchymal pattern
correlation with estrogen receptor 219-222
not a predictor of hormone therapy response 219-222
mammography
abstracts 138-141
patient preferences for learning results 223-232
markers of transformation
experimental downregulation in cells from high-risk mice 138
mastectomy
see surgery
MCF-7 human breast cancer cells
commercial charcoal-stripped serum for study of hormone action 97-104
hyperosmolality induces alkaline phosphatase and hsp27 241-249
McGuire, William L.
In Memoriam 7-15
menstrual cycle
and breast cancer-host balance 131
milk fat globule antibodies
reactivity, vs. tumor differentiation 71-76
mitoxantrone
perioperative treatment 134
molecular biology of tumor cells
abstracts 136-138
monoclonal antibody, radio-labeled
dose escalation with peripheral blood progenitor cells 183
morphologic development of the breast
effect of parity and age 211-218

neo-adjuvant therapy
abstracts 166-167
high-dose adriamycin with CSF for inflammatory breast cancer 165
node-negative breast cancer
cost-effectiveness of adjuvant chemotherapy 17-27
novobiocin
phase I trial with high-dose agents and BMT 133

oncogenes
abstracts 175-176
c-erb-B2 amplification during tumor progression 191-200
c-erbB-2 and FGF expression in mortal and immortal breast epithelial cells 174
oral contraceptives
and breast cancer risk — insights from animal studies 29-41
and breast fluid proteins 251-258

p53 gene
germline and somatic mutations 137
p53 protein
flow cytometry assay 135
in breast aspirates of high-risk women 131
in situ dephosphorylation by alkaline phosphatase treatment 137

retrieval for immunohistochemistry in over-fixed sections 150
paracrine interactions
adipocytes and estrogen biotransformation 173
effects of fibroblast cells on hormone dependent vs. independent tumor cells 172
fibroblast/epithelial cell interactions in culture 174
myoepithelial cells with MCF-7 cells in culture 138
tumor factors stimulate estradiol formation in nonmalignant tissue 51-56
parity
effect on morphologic development of the breast with age 211-218
patient education
videotape for adjuvant trials 172
patient preferences
for learning mammogram results 223-232
peripheral blood stem cell support
adjunct to high-dose therapy, abstracts 163-166
and dose escalation of radio-labeled antibody therapy 183
with high-dose chemotherapy 134
phosphoprotein 65 kDa
as a serum marker 160
physician-patient communication
patient preferences for learning mammogram results 223-232
ploidy
deviation from diploidy correlates with proliferative rate 43-49
polymerase chain reaction (PCR)
c-erb-B2 amplification in fine needle biopsies 191-200
prevention
abstracts 171
and melatonin/norethindrone oral contraceptive trial 131
progestins
and secretion of GCDFPs by T47D cells in culture 77-86
prognostic factors
abstracts 134-136, 148-154
cathepsin-D, weak association with proliferative activity 63-70
p53 gene mutations 132
urokinase system 177
prolactin receptors
and prognosis 151
proliferation markers
and prognosis 149,152,152
proliferative rate
increase with chromosome rearrangements in tumor evolution 43-49
vs. cathepsin-D content 63-70
proteins in breast fluids
vs. breast cancer, reproductive history, and oral contraceptives 251-258
psychosocial aspects of breast cancer
abstracts 172

quadrantectomy
see breast conserving treatment

race
black/white differences in breast tumor characteristics 156
radiation therapy
abstracts 167
and impaired response to hepatitis B vaccination 233-240
Mondor's disease after 156
optimal sequencing with chemotherapy 134
see also breast conserving treatment
radiology
patient preferences for learning mammogram results 223-232
reconstructive surgery
abstracts 141-142
reproductive history
and breast fluid proteins 251-258
effect on morphologic development of the breast with age 211-218
risk factors
body fat distribution in families 155
ER-positive breast epithelium 182

S-phase
see proliferative activity
San Antonio Breast Cancer Symposium, December 8-10, 1992
abstracts 131-185
program 105-130

San Antonio Flow Cytometry Forum, December 7-8, 1992
program 107-108
screening
abstracts 138-141
patient preferences for learning mammogram results 223-232
serum
charcoal-stripped, commercial 97-104
serum antibodies
in patients with breast cancer 157
serum markers
abstracts 160-161
sodium butyrate
and alkaline phosphatase, heat shock proteins 241-249
somatostatin analogues
and tamoxifen, GH-somatomedin axis 183
stage 3 breast cancer
treatment strategies 179
stage 4 breast cancer
c-erb-B2 amplification during progression 191-200
stress response proteins
see heat shock proteins
surgery
abstracts 141-142
outpatient lumpectomy, node dissection, and mastectomy 180
see also breast-conserving treatment
survival analysis
neural network application 150

T cells, tumor-reactive
expansion from axillary lymph nodes 183
T47D human breast cancer cells
steroid modulation of GCDFP secretion 77-86
tamoxifen
and depression 182
effects and IGFs 181
in breast cancer of the elderly 182
vs. chemotherapy in node+/ER+ patients 181
see also endocrine therapy
tamoxifen resistance
variant estrogen receptors 184
taxotere
phase I trials 133
TGFα
reduces estradiol formation from estrone in nonmalignant breast tissue 51-56
thymidine kinase activity
and prognosis 136
thymidine labeling index
see proliferative activity
tumor cell biology
abstracts 172-175
tumor models
MT-1 and MT-3 human breast tumors in nude mice 87-95
tumor suppressor genes
abstracts 175-176
potential products, and prognosis 135

weight gain
and adjuvant therapy 145